This atypical response was then confirmed to be present in several other solid tumors treated with PD-1 and PD-L1 inhibitors such as bladder, breast, colorectal, esophageal, gastric, head and neck, lung, pancreatoduodenal, ovarian, renal cell, sarcoma, and uterine cancer [13]. This evidence concerns the gene CD274 and uterine cancer.